Showing 1 - 10 of 103
Persistent link: https://www.econbiz.de/10014374380
Persistent link: https://www.econbiz.de/10014374515
of an increase in Danish pharmaceuticals exports. The model predicts that consumption and output increase following an …
Persistent link: https://www.econbiz.de/10015051881
International reference pricing (IRP) has become a popular policy instrument in Europe as government seeks to curb healthcare costs and notably reduce expenditure on medicines. IRP builds on systematic price comparisons with other countries and aims at fixing low reimbursement levels for drugs...
Persistent link: https://www.econbiz.de/10011790266
Competition law may play an important role in drug pricing control by containing high prices derived from economic violations. Since the use of competition tools is not limited by the TRIPS Agreement or other international binding disciplines, there is ample policy room to explore how countries,...
Persistent link: https://www.econbiz.de/10013330841
This paper examines how the courts in three developing countries (Kenya, South Africa, and India) have addressed the tension between patent rights on pharmaceutical products and the right to health. The paper begins by examining the nature of the relationship between patent rights and the right...
Persistent link: https://www.econbiz.de/10013330844
Persistent link: https://www.econbiz.de/10012490821
Persistent link: https://www.econbiz.de/10012490830
"Viral hepatitis is an international public health challenge, comparable to other major communicable diseases, including HIV, tuberculosis and malaria. Despite the significant burden it places on communities across all global regions, hepatitis has been largely ignored as a health and...
Persistent link: https://www.econbiz.de/10012490851